All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Effect of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiogram substudy

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F11%3A33148888" target="_blank" >RIV/61989592:15110/11:33148888 - isvavai.cz</a>

  • Result on the web

    <a href="http://dx.doi.org/10.1093/eurheartj/ehr311" target="_blank" >http://dx.doi.org/10.1093/eurheartj/ehr311</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1093/eurheartj/ehr311" target="_blank" >10.1093/eurheartj/ehr311</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Effect of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiogram substudy

  • Original language description

    Aims The SHIFT echocardiographic substudy evaluated the effects of ivabradine on left ventricular (LV) remodelling in heart failure (HF). Methods and results Eligible patients had chronic HF and systolic dysfunction [LV ejection fraction (LVEF) ?35%], were in sinus rhythm, and had resting heart rate ?70 bpm. Patients were randomly allocated to ivabradine or placebo, superimposed on background therapy for HF. Complete echocardiographic data at baseline and 8 months were available for 411 patients (ivabradine 208, placebo 203). Treatment with ivabradine reduced LVESVI (primary substudy endpoint) vs. placebo [?7.0 +- 16.3 vs. ?0.9 +- 17.1 mL/m2; difference (SE), ?5.8 (1.6), 95% CI ?8.8 to ?2.7, P{ 0.001]. The reduction in LVESVI was independent of beta-blocker use, HF aetiology, and baseline LVEF. Ivabradine also improved LV end-diastolic volume index (?7.9 +- 18.9 vs. ?1.8 +- 19.0 mL/m2, P= 0.002) and LVEF (+2.4 +- 7.7 vs. ?0.1 +- 8.0%, P{ 0.001). The incidence of the SHIFT primary compo

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FA - Cardiovascular diseases including cardio-surgery

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2011

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    European Heart Journal (print)

  • ISSN

    0195-668X

  • e-ISSN

  • Volume of the periodical

    32

  • Issue of the periodical within the volume

    20

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    9

  • Pages from-to

    2507-2515

  • UT code for WoS article

  • EID of the result in the Scopus database